LeBoit PE. Stroma, interrupted. Am J Dermatopathology. 2001;23:67-68.
Betti R, Menni S, Radaelli G, et al. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol. 2010;37:611-616.
Massari LP, Kastelan M, Gruber F. Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol. 2007;31(suppl 1):S83-S85.
The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer. 2007;120:1116-1122.
John AM, Schwartz RA. Basal cell naevus syndrome: an update on genetics and treatment. Br J Dermatol. 2016;174:68-76.
Ackerman AB, Gottlieb GJ. Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma. Am J Dermatopathol. 2005;27:155-159.
Bogelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of Basal cell carcinoma. Acta Derm Venereol. 2007;87:330-334.
Bukhardt Perez MP, Ruiz-Villaverde R, Naranjo Diaz MJ, et al. Basal cell carcinoma: treatment with imiquimod. Int J Dermatol. 2007;46:539-542.
Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131-1136.
Szeimies RM, Karrer S, Backer H. Therapeutic options for epithelial skin tumors: actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt. 2005;56:430-440.
Barlow JO, Zalla MJ, Kyle A, et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol. 2006;54:1039-1045.
Berking C. Photocarcinogenesis: molecular mechanisms and preventive strategies. Hautarzt. 2007;58:398-405.
1. Schwartz RA. Skin Cancer: Recognition and Management. 2nd edn. Blackwell, Oxford, United Kingdom, 2008.
2. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155:401-407.
3. Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg. 2007;11:19-30.
4. Barnhill RL, ed. Textbook of dermatopathology, 2nd ed. New York: McGraw-Hill Medical; 2004.
5. LeBoit PE. Stroma, interrupted. Am J Dermatopathology. 2001;23:67-68.
6. Betti R, Menni S, Radaelli G, et al. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol. 2010;37:611-616.
7. Skroza N, Panetta C, Schwartz RA, et al. Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat. 2006;14:46-51.
8. Ionescu DN, Arida M, Jukic DM. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med. 2006;130:45-51.
9. Sterry W; European Dermatology Forum Guideline Committee. Guidelines: the management of basal cell carcinoma. Eur J Dermatol. 2006;16:467-475.
10. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30:774-778.
11. Ormerod A, Rajpara S, Craig F. Basal cell carcinoma. BMJ Clinical Evid. April 2010. http://clinicalevidence.bmj.com (last accessed 21 July 2016).
12. Reifenberger J. Basal cell carcinoma: molecular genetics and unusual clinical features. Hautarzt. 2007;58:406-411.
13. Balk SJ; Council on Environmental Health; Section on Dermatology. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics. 2011;127:e791-e817.
14. Sellheyer K. Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers. Br J Dermatol. 2011;164:696-711.
15. Massari LP, Kastelan M, Gruber F. Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol. 2007;31(suppl 1):S83-S85.
16. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer. 2007;120:1116-1122.
17. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24:715-719.
18. Marin-Gutzke M, Sanchez-Olaso A, Berenguer B, et al. Basal cell carcinoma in childhood after radiation therapy: case report and review. Ann Plast Surg. 2004;53:593-595.
19. Yu HS, Liao WT, Chai CY. Arsenic carcinogenesis in the skin. J Biomed Sci. 2006;13:657-666.
20. Rossy KM, Janusz CA, Schwartz RA. Cryptic exposure to arsenic. Indian J Dermatol Venereol Leprol. 2005;71:230-235.
21. Miller KL, Karagas MR, Kraft P, et al. XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis. 2006;27:1670-1675.
22. Boonen SE, Stahl D, Kreiborg S, et al. Delineation of an interstitial 9q22 deletion in basal cell nevus syndrome. Am J Med Genet A. 2005;132:324-328.
23. de Meij TG, Baars MJ, Gille JJ, et al. From gene to disease: basal cell naevus syndrome. Ned Tijdschr Geneeskd. 2005;149:78-81.
24. Pastorino L, Cusano R, Nasti S, et al. Molecular characterization of Italian nevoid basal cell carcinoma syndrome patients. Hum Mutat. 2005;25:322-323.
25. Ragge NK, Salt A, Collin JR, et al. Gorlin syndrome: the PTCH gene links ocular developmental defects and tumour formation. Br J Ophthalmol. 2005;89:988-991.
26. John AM, Schwartz RA. Basal cell naevus syndrome: an update on genetics and treatment. Br J Dermatol. 2016;174:68-76.
27. Kanitakis J, Alhaj-Ibrahim L, Euvrard S, et al. Basal cell carcinomas developing in solid organ transplant recipients: clinicopathologic study of 176 cases. Arch Dermatol. 2003;139:1133-1137.
28. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;154:190-201.
29. US Preventive Services Task Force. Screening for skin cancer. February 2009. http://www.uspreventiveservicestaskforce.org/ (last accessed 21 July 2016).
30. Marrett L, Rosen L, Zwaal C, et al; Cancer Care Ontario. Screening for skin cancer: a clinical practice guideline. June 2007. http://www.cancercare.on.ca (last accessed 21 July 2016).
31. Mogensen M, Jemec GB. Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg. 2007;33:1158-1174.
32. Stulberg D, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinomas. Am Fam Physician. 2004;70:1481-1488.
33. Smeets NW, Stavast-Kooy AJ, Krekels GA, et al. Adjuvant cytokeratin staining in Mohs micrographic surgery for basal cell carcinoma. Dermatol Surg. 2003;29:375-377.
34. Ackerman AB, Gottlieb GJ. Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma. Am J Dermatopathol. 2005;27:155-159.
35. Helm KF, Cowen EW, Billingsley EM, et al. Trichoblastoma or trichoblastic carcinoma? J Am Acad Dermatol. 2001;44:547.
36. Marek L, Grzanka A, Chmielowska E, et al. Merkel cell carcinoma: an illustrative case and review. Postepy Dermatol Alergol. 2014;31:325-328.
37. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;(1):CD003412.
38. Micali G, Lacarrubba F, Nasca MR, et al. Topical pharmacotherapy for skin cancer: part II. Clinical applications. J Am Acad Dermatol. 2014;70:979.
39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: basal cell skin cancer. May 2016. http://www.nccn.org (last accessed 21 July 2016).
40. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180-2188.
41. Bogelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of Basal cell carcinoma. Acta Derm Venereol. 2007;87:330-334.
42. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: basal cell skin cancer. September 2017. https://www.nccn.org/ (last accessed 21 September 2017).
43. Dixon AJ. Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy. Aust Fam Physician. 2005;34:49-52.
44. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007;143:266-268.
45. Karve SJ, Feldman SR, Yentzer BA, et al. Imiquimod: a review of basal cell carcinoma treatments. J Drugs Dermatol. 2008;7:1044-1051.
46. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:96-105.
47. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647-654.
48. Bukhardt Perez MP, Ruiz-Villaverde R, Naranjo Diaz MJ, et al. Basal cell carcinoma: treatment with imiquimod. Int J Dermatol. 2007;46:539-542.
49. Orenberg EK, Miller BH, Greenway HT, et al. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol 1992;27:723-728.
50. Wrone DA. 5-Fluorouracil versus surgery in superficial basal cell carcinoma and other skin malignancies. Cos Derm. 2004;17(suppl 3):S7-S10.
51. Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35-48.
52. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol. 2007;56:125-143.
53. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131-1136.
54. Apalla Z, Sotiriou E, Chovarda E, et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization: a randomized placebo-controlled study. Br J Dermatol. 2010;162:171-175.
55. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011;25:896-901.
56. Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. J Am Acad Dermatol. 2009;60:137-143.
57. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-2179.
58. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4:462-469.
59. Szeimies RM, Karrer S, Backer H. Therapeutic options for epithelial skin tumors: actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt. 2005;56:430-440.
60. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32:63-69.
61. Barlow JO, Zalla MJ, Kyle A, et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol. 2006;54:1039-1045.
62. Berlin JM, Leeman DR, Spunberg JJ, et al. Radiotherapy for rodent ulcer type of basal cell carcinoma. Dermatol Surg. 2007;33:513-515.
63. Hirschsteiner O, Maiwald G, Balda BR. Guess what! Diagnosis: extended ulcerating metatypical basal cell carcinoma (BCC) with soft tissue and bone destruction. Eur J Dermatol. 2000;10:315-316.
64. Berking C. Photocarcinogenesis: molecular mechanisms and preventive strategies. Hautarzt. 2007;58:398-405.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台